UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of
report (Date of earliest event reported): January 4, 2011 (December 29,
2010)
SKYSTAR BIO-PHARMACEUTICAL
COMPANY
(Exact
name of registrant as specified in Charter)
|
Nevada
|
001-34394
|
33-0901534
|
|
(State
or other jurisdiction ofincorporation or organization)
|
(Commission
File No.)
|
(IRS
Employer Identification
No.)
|
Room 10601, Jiezuo Plaza, No.4,
Fenghui Road South
Gaoxin District, Xi’an, Shaanxi
Province
People’s Republic of
China
(Address
of Principal Executive Offices)
(8629) 8819-3188
(Issuer
Telephone Number)
N/A
(Former name or former address, if
changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.07. Submission of Matters
to a Vote of Security Holders
On
December 29, 2010, the Registrant held its Annual Meeting of Shareholders to
elect seven (7) directors to the Registrant’s Board of Directors to hold office
until the next annual meeting and until their successors are duly elected and
qualified. A quorum, however, was not reached to transact business at
the meeting, but the following votes were cast for each of the seven (7)
director-nominees:
|
Name of Nominee
|
Votes For
|
Votes Withheld
|
||||
|
Weibing
Lu
|
3,175,125
|
9,912
|
||||
|
Wei
Wen
|
3,175,125
|
9,912
|
||||
|
Mark
D. Chen
|
3,043,441
|
141,596
|
||||
|
R.
Scott Cramer
|
3,175,125
|
9,912
|
||||
|
Qiang
Fan
|
3,177,079
|
7,958
|
||||
|
Chengtun
Qu
|
3,182,079
|
2,958
|
||||
|
Shouguo
Zhao
|
3,177,079
|
7,958
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date:
January 4, 2011
|
Skystar
Bio-Pharmaceutical Company
(Registrant)
|
|
|
By:
/s/ Weibing
Lu
|
||
|
Weibing
Lu
|
||
|
Chief
Executive Officer
|